17 results about "Cellular Regulation" patented technology

The invention relates to a biological information data processing technology, in particular to a method for analyzing a single-cell Hi-C regulation scale chromatin band, which comprises the following steps: preprocessing single-cell Hi-C data to generate pseudo-batch Hi-C data; performing normalization processing on the pseudo batch Hi-C data to extract a Hi-C contact matrix of each chromosome; identifying and detecting false batch strips from the Hi-C contact matrix; projecting the pseudo batch strips to the original single cell Hi-C data to obtain single cell strips; and carrying out quantitative analysis on the single-cell strip in the original single-cell Hi-C data. According to the method, the regulation and control scale chromatin bands with definite endpoints and directivity can be stably identified, and a band set with remarkable statistics is output.

The invention discloses a method for producing MK-7 through whole-cell regulation and control by using different time sequence type promoters, recombinant escherichia coli and application. According to the method, the time sequence type promoters are used for regulating and controlling expression of different key genes related to MK-7 synthesis. According to the invention, the time sequence promoter is used for whole-cell regulation and control to produce the vitamin MK-7 for the first time, dynamic regulation of the MK-7 is realized, and the production efficiency of the MK-7 can be remarkably improved by accurately regulating and controlling expression of key genes in a synthesis route of the MK-7 and optimizing an intracellular metabolic process. The promoter disclosed by the invention can regulate cell metabolism and enhance synthesis of MK-7 in different growth stages or under different environmental conditions by controlling the time and strength of gene expression. The MK-7 is produced by adopting the constructed recombinant escherichia coli obtained based on whole-cell regulation of the sequential promoter, and the yield of 14 g / L can be finally achieved in a 5L fermentation tank.

The present invention provides a dual DNA tetrahedron structure, a preparation method and an application thereof. The dual DNA tetrahedron of the present invention includes a first DNA tetrahedron structure, a second DNA tetrahedron structure and a connecting chain. This structure can specifically recognize two cell surface proteins and be labeled by fluorescence; at the same time, due to the steric hindrance effect of the structure, it is difficult for the two proteins to approach each other, affecting the interaction between the two. This structure can exist on the cell surface for a long time, thus having a good cell regulation effect on these two cell membrane surface proteins, specifically reflected in reducing the phosphorylation level of HER2 protein, promoting the expression of apoptosis-related proteins, and ultimately leading to apoptosis of tumor cells and reducing the cell activity of tumor cells.

The present application relates to biological information data processing technology, and is a method for single-cell Hi-C regulatory scale chromatin band analysis, comprising the following steps: preprocessing single-cell Hi-C data to generate pseudo-bulk Hi-C data; normalizing the pseudo-bulk Hi-C data to extract the Hi-C contact matrix of each chromosome; identifying and detecting pseudo-bulk bands from the Hi-C contact matrix; projecting the pseudo-bulk bands onto the original single-cell Hi-C data to obtain single-cell bands; and quantitatively analyzing the single-cell bands in the original single-cell Hi-C data. The present application can stably identify regulatory scale chromatin bands with clear endpoints and directionality, and output statistically significant band sets.

This invention relates to a liposomal formulation based on myeloid cell regulation and chemotherapy enhancement, along with its preparation method and antitumor applications, belonging to the technical field of pharmaceutical formulations. The liposomal formulation uses liposomes as carriers to co-load the CD11b agonist leukadherin-1 (LA1) prodrug (DSPE-PEG2000-Azo-LA1) and the gemcitabine prodrug Gem-SS-Chol. DSPE-PEG2000-Azo-LA1 contains a hypoxia-responsive azobenzene linker, and Gem-SS-Chol contains a glutathione-responsive disulfide bond, enabling precise drug release within the tumor microenvironment. This formulation exhibits uniform particle size and good stability, synergistically exerting chemotherapeutic and immunomodulatory effects. It effectively inhibits the proliferation and migration of pancreatic cancer tumor cells, enhances tumor cell immunogenic cell death, regulates the phenotype of myeloid immune cells in the tumor immunosuppressive microenvironment, and improves the therapeutic effect of pancreatic cancer. This invention provides a novel and highly efficient liposomal formulation for pancreatic cancer treatment, focusing on myeloid cell regulation and chemotherapy enhancement.

The invention relates to an up-conversion nanoparticle compound, a preparation method thereof and a cell regulation substrate, the up-conversion nanoparticle compound comprises up-conversion nanoparticles, connecting molecules connected to the surfaces of the up-conversion nanoparticles, and light-operated isomeric molecules reversibly connected with the connecting molecules, rGD polypeptide is connected to the light-controlled isomeric molecule; wherein the upconversion nano-particles can convert near-infrared light irradiated on the upconversion nano-particles into ultraviolet light, and after the light-operated isomeric molecules connected with the RGD polypeptide are radiated by the ultraviolet light, the light-operated isomeric molecules and the RGD polypeptide fall off from the connecting molecules together. The up-conversion nanoparticle compound can be applied to a carrier for cell growth, and is irradiated by near-red light in the cell growth process to dynamically regulate and control cell adhesion, extension and differentiation.

This invention relates to the field of cell regulation technology and discloses a multi-parameter feedback-based intelligent regulation method for Chir99021-induced differentiation of dental pulp stem cells. The method includes: acquiring a dataset of the differentiation process of dental pulp stem cells and performing structured analysis to obtain a multi-parameter monitoring dataset; performing multi-dimensional assessment of cell differentiation status to obtain a differentiation status assessment characterization; obtaining drug release regulation parameters based on the differentiation status assessment characterization and historical differentiation trend data; performing multi-dimensional planning on the differentiation status assessment characterization and drug release regulation parameters to obtain a regulation strategy, and encoding and reconstructing the regulation strategy to obtain microenvironment regulation instructions; applying the microenvironment regulation instructions to obtain an optimized culture microenvironment and monitoring cell state information in the optimized culture microenvironment; and iteratively regulating the drug release regulation parameters based on the cell state information to obtain the final regulation instructions. This invention can improve the accuracy of Chir99021-induced differentiation regulation of dental pulp stem cells.

The method of generating multipotent stem cells is a method for producing and / or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1− / − murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.

The invention discloses a system and a method for realizing cell regulation and control based on luminous oscillation stimulation of cell nucleuses, and relates to the technical field of crossing of biotechnology and optical micro-control. The method comprises the following steps: internalizing biocompatible microspheres beside a living cell nucleus, capturing the microspheres by using an optical tweezers module, and driving a light potential well to carry out double-position high-speed alternate switching by using a parameter control unit, so as to construct a programmable optical mechanical oscillator to apply oscillation stimulation to cells in a set direction, frequency and amplitude. According to the invention, the limitation of the traditional method is broken through, and direct and controllable mechanical stimulation and observation on the cell nucleus in the living cell are realized.

The invention discloses a photo-thermal temperature-sensitive cell membrane drug delivery system capable of controlling drug release as well as a preparation method and application of the photo-thermal temperature-sensitive cell membrane drug delivery system. The delivery system comprises a cell membrane carrier, and temperature-sensitive lipid and a photosensitizer are doped in the cell membrane carrier. According to the scheme, the thermo-sensitive lipid and the photosensitizer are ingeniously introduced into a cell membrane delivery system at the same time, photo-thermal controllable drug depolymerization and release after target tissue arrives are achieved, then the drug is accurately delivered to heterotarget cells, and the treatment effects of disease tissue targeting and multi-cell regulation are achieved. The design obviously exceeds the limitation of a traditional cell membrane nano-drug delivery system, the traditional cell membrane nano-drug delivery system is only limited to targeting of a single cell type, and the action range is relatively limited.

The invention relates to a strong-field terahertz cell irradiator, belongs to the field of terahertz biological state regulation and control and the field of experimental technical equipment, and solves the technical problems that a cell regulation and control system based on a strong-field terahertz radiation source does not exist in the prior art and the existing system does not have a portable and movable function. The strong-field terahertz cell irradiator comprises a mounting platform, a strong-field terahertz source module and a cell irradiation module. The system is portable and movable, and is suitable for diversified scenes. The system is high in integration level, the average power of the terahertz waves is high, the monopulse terahertz energy is high, the energy of the terahertz waves irradiated on the biological substances is ensured, the high field intensity enables the terahertz waves to generate a regulation effect with the biological substances more easily, and the state regulation of the strong-field terahertz waves on the biological substances can be better researched.

The application provides a system for on-demand regulation of cell behavior based on host-guest recognition space reversible rearrangement of cell receptors and application thereof, and the system comprises a beta-cyclodextrin polymer, a Met binding nucleic acid aptamer labeled with ferrocene and adamantane. Linear beta-cyclodextrin polymer and cross-linked beta-cyclodextrin polymer are used in the system. The two kinds of beta-cyclodextrin polymers have different regulation effects on cell receptors. The system composed of linear beta-cyclodextrin polymer can sensitively rearrange Met receptors to significantly inhibit HGF-induced Met receptor activation, block related signal pathways and indirectly regulate cell behavior. The system composed of cross-linked beta-cyclodextrin polymer can activate cell receptors and directly regulate cell behavior. The system can be applied to preparation of a detection kit for cell analysis and preparation of a drug for cell regulation to regulate the phosphorylation level of Met receptors, cell proliferation and cell migration behavior on demand.

The application relates to the technical field of biomaterials, in particular to a stem cell aggregate-derived decellular extracellular matrix and application thereof in bone defect repair. The decellular extracellular matrix is formed by subjecting a 3D cell aggregate in the form of a sphere to decellularization treatment, and the 3D cell aggregate is induced to form by transferring adult bone marrow mesenchymal stem cells after culture to a low-absorption cell culture carrier. The 3D dECM has a complete three-dimensional scaffold structure and abundant pores, while retaining key extracellular matrix components such as collagen, fibronectin and laminin, and is closer to the in-vivo tissue microenvironment; the 3D dECM significantly enhances the migration ability of cells, effectively improves the stemness of BMSCs, promotes extracellular matrix synthesis, and improves the mitochondrial function of BMSCs, has excellent cell regulation ability and functional activity, and thus solves the problems of low bioactivity and insufficient bionics of traditional 2D dECM.

The invention belongs to the technical field of biological medicines, and discloses an immunoregulation method for directional differentiation of CD4 + T cells. According to the method, an intelligent response type three-dimensional support composed of a temperature-sensitive block copolymer, MMP degradable peptide and a pH-sensitive component is constructed, a space-time nest is formed in situ at a focus, three active molecules including vorinostat, IL-6 / rapamycin and TGF-beta1 / retinoic acid are loaded by adopting a layered drug loading strategy, dynamic release is performed according to a microenvironment, and the pH-sensitive drug-loaded vorinostat / IL-6 / rapamycin / TGF-beta1 / retinoic acid is obtained. The efficient, lasting and antigen-specific directional induction of CD4 + T cells to subgroups such as Treg or Th17 is realized. The method is not only suitable for various disease scenes such as tumors, autoimmune diseases and chronic inflammation, but also can flexibly adapt to different T cell subpopulation induction requirements by replacing loaded bioactive molecule combinations and antigen peptide sequences, the local T cell regulation efficiency can be remarkably improved, systemic toxicity is avoided, and the method is suitable for clinical application. And good biocompatibility and clinical transformation potential are achieved.

The present invention relates to compositions and methods for subpopulation-specific modulation of cell function through spatiochemical and spatiotemporal control over intracellular regulatory protein networks at the level of expressed gene products of nucleic acid-binding protein (NABP) genes. Subpopulation-specific cytoactive agents of the invention are used in therapeutic compositions that up- or downregulate disease-associated intracellular regulatory protein genes at the RNA and protein level for prevention and treatment of plant, animal and human diseases. Applications in human clinical medicine include biopharmaceutical preparations and associated treatment methods for genetic, degenerative, neurological, cellular and immune disorders resulting from dysregulation of endogenous NABP regulatory networks. Therapeutic compositions designed or selected for use in plants and nonhuman animals are applied to the fields of agriculture and veterinary medicine. Also provided are research kits for subpopulation-specific modulation of protein activity and the corresponding potential to discover novel therapeutic compositions across fields. More specifically, the disclosed compositions and methods selectively up- or downregulate at least a first subpopulation of a cellular protein or therapeutic target without substantially altering the activity of at least a second subpopulation of the cellular protein or therapeutic target.

The present invention discloses a device and method for quantitatively detecting CREPT protein based on a resonant QCM biosensor. By constructing a circular concave area on the base, embedding a silica gel ring at the bottom of the concave area of the base, and placing the resonant QCM biosensor on the silica gel ring. On this basis, a hollow cylinder is placed on the base, and the circular through-hole is adapted to the circular concave area, so that the highly sensitive resonant QCM biosensor can be used to quantitatively detect CREPT protein. During quantitative detection, first, the pressure-frequency sensitivity coefficient K<subgt;Pf< / subgt; and the pressure-frequency coefficient C<subgt;Pf< / subgt> are calibrated, and then the obtained HA-3HA tag protein liquid and HA-3HA-CREPT protein liquid are respectively added to the surface of the upper electrode of the QCM biosensor. After the surface of the upper electrode is completely covered, according to the difference in the change in resonant frequency and the added amount, the content of CREPT protein is calculated. In this way, the low-cost and real-time online quantitative detection of the biomarker of early tumor cells - the protein for tumor cell regulation and evaluation is realized, and then the quantitative detection of the degree of early tumor carcinogenesis is achieved.

The present invention provides a liposome drug delivery system targeting neutrophil PD-L1, its preparation method, and application, belonging to the field of biomedicine. This liposome drug delivery system targeting neutrophil PD-L1 has the following characteristics: a neutrophil-specific antibody or polypeptide, a liposome, and a PD-L1-specific siRNA, wherein the neutrophil-specific antibody or polypeptide is covalently bound to the liposome surface, and the PD-L1-specific siRNA is encapsulated within the liposome. Experimental results have shown that this liposome drug delivery system targeting neutrophil PD-L1 can be delivered to neutrophils, exerting cellular regulatory effects and intervening in sepsis, acute respiratory distress syndrome, and multiple organ dysfunction syndrome.